Mark Lacy
About Mark Lacy
Mark Lacy Founder & Chief Executive Officer
Mark Lacy is the Founder and Chief Executive Officer of an organization known for its contributions to the life sciences industry. His leadership role involves overseeing business strategy, operations, and corporate development. Lacy's vision has driven the organization's growth and innovation in clinical research and eClinical trial management services.
Innovation in Clinical Research Award 2016
In 2016, Mark Lacy received the Innovation in Clinical Research Award. This accolade acknowledges significant contributions and advancements in clinical research methodologies and practices. It is a testament to his innovative approach and dedication to improving the efficiency and effectiveness of clinical trials.
Entrepreneur Magazine's Entrepreneur of the Year Runner-Up 2010
In 2010, Mark Lacy was a runner-up for Entrepreneur Magazine's Entrepreneur of the Year. This recognition highlights his entrepreneurial spirit, leadership, and impact on the industry. Being a runner-up in such a prestigious competition underlines his notable achievements and business acumen.
100 Most Inspiring People in Life Sciences by PharmaVoice Magazine 2011
In 2011, Mark Lacy was listed among the 100 Most Inspiring People in the Life Sciences Industry by PharmaVoice Magazine. This inclusion reflects his influence and contribution to the life sciences field, recognizing his efforts to inspire and drive progress within the industry.
Top 10 eClinical Trial Management Service Companies in 2021 by PharmaTech Outlook
Mark Lacy was featured on the cover of PharmaTech Outlook in 2021, identifying his company as one of the Top 10 eClinical Trial Management Service Companies. This feature showcases the company's excellence and leadership in providing advanced eClinical trial management solutions.
50 Most Influential People in Vaccines Industry by VaccineNation 2014
Mark Lacy was recognized by VaccineNation.org as one of the 50 Most Influential People in the Vaccines Industry in September 2014. This recognition underscores his significant impact and influence in the vaccines sector, highlighting his role in advancing vaccine-related research and development.